- Origin: MO
- Grant awarded in: 2015
Chief Operating Officer
Chief Financial Officer
Chief Scientific Officer
What is Hemadvance?
Developing next generation bio-therapeutic molecules to diagnose, manage and treat the onset and progression of coagulation disorders.
Barbara Hawatmeh Pozzi
Barbara Hawatmeh Pozzi is the Chief Operating Officer of Hemadvance, a 2015 Arch Grants Recipient.
Barbara earned her B.S. in Business Administration from Boston University and holds a J.D. from Washington University in St. Louis, as well as a Master of Law degree from European University Institute in Italy. She brings experience as counsel for a corporation and as founder of Digital Medical Arts, LLC a medical software company to her position with Hemadvance. She also currently serves as an Adjunct Assistant Professor at St. Louis University's School for Professional Studies.
Nicola Pozzi is the Founder of Hemadvance, a 2015 Arch Grants Recipient.
Nicola earned his B.S. and M.S. in Chemistry and Pharmaceutical Technology from the University of Padua in Italy, and holds a PhD in Molecular Sciences - Biochemistry and Biophysics. He currently serves as a faculty member of the Saint Louis University.
Christine Allison is the Chief Financial Officer of Hemadvance, a 2015 Arch Grants Recipient.
Christine earned her B.S. in Accounting from Bradley University and holds an MBA from Saint Louis University. She brings extensive corporate experience in finance to her position with Hemadvance, including work in cash management, financial analysis, risk management, pension investment, working capital management, and banking.
Sergio Barranco is the Chief Scientific Officer of Hemadvance, a 2015 Arch Grants Recipient.
Sergio earned his Pharmacy degree from the University of Granada, Spain and holds a PhD in Biochemistry and Molecular Biology. He brings 15 years of pharmaceutical research experience to his position with Hemadvance.